

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

POSITIVE PROFIT ALERT

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on a review of the Group’s preliminary unaudited consolidated management accounts for the six months ended June 30, 2024 (the “**Reporting Period**”), the Group is expected to achieve a revenue of not less than RMB360.0 million, representing an increase of not less than approximately 56.5% as compared to that of RMB230.1 million for the six months ended June 30, 2023. We also expect to record a net profit attributable to the equity holders of the Company of not less than RMB50.0 million, as compared to the net loss of approximately RMB35.5 million for the six months ended June 30, 2023. The expected profit is mainly attributable to revenue increase driven by our comprehensive and high-quality product portfolio, our strategic sales and marketing efforts in both domestic and international markets, and operating efficiency improvement attributable to continuous optimization of our production and supply chain and enhanced capacity utilization.

As the Group’s consolidated financial results for the Reporting Period have not yet been finalized, the information contained in this announcement is based on information that is currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period which have not yet been reviewed by the Company’s auditors or audit committee. The actual financial results of the Group for the Reporting Period, which may be subject to adjustment(s) and which may differ from the information contained in this announcement, are expected to be published before the end of August 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, July 29, 2024

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.